Barclays analyst Matt Miksic lowered the firm’s price target on DexCom (DXCM) to $92 from $113 and keeps an Equal Weight rating on the shares.

DexCom, Inc. DXCM reported strong preliminary results for the fourth quarter and full-year 2024. In response, the company’s stock jumped 2.7% on Jan. 13. The company is scheduled to release its fourth ...

Baird upgraded DexCom Inc (NASDAQ:DXCM). to "Outperform" from "Neutral," citing progress in U.S. sales and upcoming catalysts. The price target was raised to $104 from $98.

DexCom's stock is fairly valued despite positive Q4 2024 results, with muted enthusiasm from Wall Street today. Click here to ...

In a report released today, Jeff Johnson from Robert W. Baird upgraded Dexcom (DXCM – Research Report) to a Buy, with a price target of ...

After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have diabetes, Dexcom said it expects to see more than $4.0 | The blood sugar tracking ...

Kevin Sayer said at the J.P. Morgan Healthcare Conference that Dexcom also expects to release a 15-day glucose sensor in the ...

DexCom (NASDAQ:DXCM – Free Report) had its price objective boosted by Wells Fargo & Company from $90.00 to $94.00 in a report published on Wednesday morning,Benzinga reports.The firm currently ...

Dexcom CEO Kevin Sayer shared new data on the company’s first over-the-counter glucose sensor at the J.P. Morgan Healthcare Conference on Monday. Stelo, which is indicated for people who don’t ...